Molecular diagnostics is becoming a dominant platform in clinical medicine and represents one of the fastest growing segments of the diagnostics market. Many molecular tests are CE Marked and FDA-cleared and many more are in development. However many more unique tests have been launched as test services, especially for cancer management and infectious disease epidemiology.
In light of the amount of activity in test development and regulatory and reimbursement challenges in 2013, Kalorama Information presents this updated review of molecular diagnostics with an emphasis on the last six months of 2013: July – December. This report highlights trends and developments that portent the evolution of molecular tests and technologies. The ensemble of consumer demand, technological advances and market forces create a dynamic, energetic and fast-moving environment for new tests and companies.
Though focused on the developments of the last six months, coverage is substantial. As part of its coverage, this report provides, current market size and forecasts for Molecular Diagnostic Segments, including:
The report provides breakout of key market segments for molecular diagnostic markets in world regions, including developed nations and emerging nations. In addition the following important trend information is also provided:
-Selected Sequencing-Based Innovations July-December 2013
-Selected Molecular Diagnostics Collaborations, July-December 2013
-Selected Molecular Diagnostics Licensing Agreements, July-December 2013
-Selected Molecular Diagnostics Distribution Agreements, July-December 2013
-Regulatory and Reimbursement Update
-Molecular Test Revenues of The Top Companies, 2012-2013
Market analysis in this report covers world markets for in vitro diagnostics, however the reader will find a bias toward the developed areas of the globe — North America and Western Europe. However public health and infectious disease are a growing global problem and where possible the report covers IVD products related to the globalization of diseases. The information presented in this report is derived primarily from company reports and other publicly available information published by government, and medical organizations.